Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Hepatitis

  Free Subscription


Articles published in Gut

Retrieve available abstracts of 55 articles:
HTML format
Text format



Single Articles


    February 2017
  1. VAN RENNE N, Roca Suarez AA, Duong FH, Gondeau C, et al
    miR-135a-5p-mediated downregulation of protein tyrosine phosphatase receptor delta is a candidate driver of HCV-associated hepatocarcinogenesis.
    Gut. 2017 Feb 3. pii: gutjnl-2016-312270. doi: 10.1136/gutjnl-2016-312270.
    PubMed     Text format     Abstract available


    January 2017
  2. MENARD A, Aherfi S, Mokhtari S, Dhiver C, et al
    Toward chronic hepatitis C eradication in HIV-positive patients, including those cirrhotic and infected with genotype 3 viruses.
    Gut. 2017 Jan 10. pii: gutjnl-2016-313431. doi: 10.1136/gutjnl-2016-313431.
    PubMed     Text format    


  3. BUDKOWSKA A
    Intriguing structure of the HCV particle.
    Gut. 2017 Jan 5. pii: gutjnl-2016-313184. doi: 10.1136/gutjnl-2016-313184.
    PubMed     Text format    


    December 2016

  4. Erratum: Daclatasvir plus sofosbuvir, with or without ribavirin, achieved high sustained virological response rates in patients with HCV infection and advanced liver disease in a real-world cohort.
    Gut. 2016;65:2060.
    PubMed     Text format    


    November 2016
  5. SUGARMAN J, Revill P, Zoulim F, Yazdanpanah Y, et al
    Ethics and hepatitis B cure research.
    Gut. 2016 Nov 14. pii: gutjnl-2016-313009. doi: 10.1136/gutjnl-2016-313009.
    PubMed     Text format    


  6. ROINGEARD P, Dreneau J, Meunier JC
    Unravelling the multiple roles of apolipoprotein E in the hepatitis C virus life cycle.
    Gut. 2016 Nov 3. pii: gutjnl-2016-312774. doi: 10.1136/gutjnl-2016-312774.
    PubMed     Text format    


    October 2016
  7. YOKOKAWA H, Higashino A, Suzuki S, Moriyama M, et al
    Induction of humoural and cellular immunity by immunisation with HCV particle vaccine in a non-human primate model.
    Gut. 2016 Oct 26. pii: gutjnl-2016-312208. doi: 10.1136/gutjnl-2016-312208.
    PubMed     Text format     Abstract available


  8. PIVER E, Boyer A, Gaillard J, Bull A, et al
    Ultrastructural organisation of HCV from the bloodstream of infected patients revealed by electron microscopy after specific immunocapture.
    Gut. 2016 Oct 11. pii: gutjnl-2016-311726. doi: 10.1136/gutjnl-2016-311726.
    PubMed     Text format     Abstract available


    September 2016
  9. CROUCHET E, Lefevre M, Verrier ER, Oudot MA, et al
    Extracellular lipid-free apolipoprotein E inhibits HCV replication and induces ABCG1-dependent cholesterol efflux.
    Gut. 2016 Sep 8. pii: gutjnl-2015-311289. doi: 10.1136/gutjnl-2015-311289.
    PubMed     Text format     Abstract available


  10. WELZEL TM, Petersen J, Herzer K, Ferenci P, et al
    Daclatasvir plus sofosbuvir, with or without ribavirin, achieved high sustained virological response rates in patients with HCV infection and advanced liver disease in a real-world cohort.
    Gut. 2016 Sep 7. pii: gutjnl-2016-312444. doi: 10.1136/gutjnl-2016-312444.
    PubMed     Text format     Abstract available


    August 2016
  11. BEILSTEIN F, Lemasson M, Pene V, Rainteau D, et al
    Lysophosphatidylcholine acyltransferase 1 is downregulated by hepatitis C virus: impact on production of lipo-viro-particles.
    Gut. 2016 Aug 31. pii: gutjnl-2016-311508. doi: 10.1136/gutjnl-2016-311508.
    PubMed     Text format     Abstract available


  12. HUTIN YJ, Wiktor SZ
    Prioritising treatment among people who inject drugs in order to eliminate hepatitis C: addressing reluctance with sound economic analyses.
    Gut. 2016 Aug 26. pii: gutjnl-2016-312636. doi: 10.1136/gutjnl-2016-312636.
    PubMed     Text format    


  13. BAYLISS J, Yuen L, Rosenberg G, Wong D, et al
    Deep sequencing shows that HBV basal core promoter and precore variants reduce the likelihood of HBsAg loss following tenofovir disoproxil fumarate therapy in HBeAg-positive chronic hepatitis B.
    Gut. 2016 Aug 17. pii: gutjnl-2015-309300. doi: 10.1136/gutjnl-2015-309300.
    PubMed     Text format     Abstract available


  14. EL-KHAYAT HR, Fouad YM, Maher M, El-Amin H, et al
    Efficacy and safety of sofosbuvir plus simeprevir therapy in Egyptian patients with chronic hepatitis C: a real-world experience.
    Gut. 2016 Aug 10. pii: gutjnl-2016-312012. doi: 10.1136/gutjnl-2016-312012.
    PubMed     Text format     Abstract available


    July 2016
  15. LIU CH, Lin CC, Hsu WC, Chung CY, et al
    Highly bioavailable silibinin nanoparticles inhibit HCV infection.
    Gut. 2016 Jul 19. pii: gutjnl-2016-312019. doi: 10.1136/gutjnl-2016-312019.
    PubMed     Text format     Abstract available


  16. WELZEL TM, Nelson DR, Morelli G, Di Bisceglie A, et al
    Effectiveness and safety of sofosbuvir plus ribavirin for the treatment of HCV genotype 2 infection: results of the real-world, clinical practice HCV-TARGET study.
    Gut. 2016 Jul 13. pii: gutjnl-2016-311609. doi: 10.1136/gutjnl-2016-311609.
    PubMed     Text format     Abstract available


  17. SHIMAKAWA Y, Bonnard P, El Kassas M, Abdel-Hamid M, et al
    Diagnostic accuracy of the gamma-glutamyl transpeptidase to platelet ratio to predict liver fibrosis in Egyptian patients with HCV genotype 4.
    Gut. 2016 Jul 7. pii: gutjnl-2016-312326. doi: 10.1136/gutjnl-2016-312326.
    PubMed     Text format    


    June 2016
  18. GOUTTENOIRE J, Szkolnicka D, Moradpour D
    Treatment of chronic hepatitis E with ribavirin: lessons from deep sequencing.
    Gut. 2016 Jun 22. pii: gutjnl-2016-312040. doi: 10.1136/gutjnl-2016-312040.
    PubMed     Text format    


  19. STICKEL F, Dubuquoy L
    MicroRNA in alcoholic hepatitis: implications for pathophysiology and treatment.
    Gut. 2016 Jun 1. pii: gutjnl-2016-312101. doi: 10.1136/gutjnl-2016-312101.
    PubMed     Text format    


    May 2016
  20. TODT D, Gisa A, Radonic A, Nitsche A, et al
    In vivo evidence for ribavirin-induced mutagenesis of the hepatitis E virus genome.
    Gut. 2016 May 24. pii: gutjnl-2015-311000. doi: 10.1136/gutjnl-2015-311000.
    PubMed     Text format     Abstract available


  21. WANG L, Xia J, Wang L, Wang Y, et al
    Experimental infection of rabbits with genotype 3 hepatitis E virus produced both chronicity and kidney injury.
    Gut. 2016 May 10. pii: gutjnl-2016-312023. doi: 10.1136/gutjnl-2016-312023.
    PubMed     Text format    


  22. BLAYA D, Coll M, Rodrigo-Torres D, Vila-Casadesus M, et al
    Integrative microRNA profiling in alcoholic hepatitis reveals a role for microRNA-182 in liver injury and inflammation.
    Gut. 2016 May 10. pii: gutjnl-2015-311314. doi: 10.1136/gutjnl-2015-311314.
    PubMed     Text format     Abstract available


    April 2016
  23. FISCHER J, Weber AN, Bohm S, Dickhofer S, et al
    Sex-specific effects of TLR9 promoter variants on spontaneous clearance of HCV infection.
    Gut. 2016 Apr 21. pii: gutjnl-2015-310239. doi: 10.1136/gutjnl-2015-310239.
    PubMed     Text format     Abstract available


  24. SCOTT N, McBryde ES, Thompson A, Doyle JS, et al
    Treatment scale-up to achieve global HCV incidence and mortality elimination targets: a cost-effectiveness model.
    Gut. 2016 Apr 12. pii: gutjnl-2016-311504. doi: 10.1136/gutjnl-2016-311504.
    PubMed     Text format     Abstract available


  25. BOYD A, Bottero J, Lacombe K
    The gamma-glutamyl transpeptidase-to-platelet ratio as a predictor of liver fibrosis in patients co-infected with HBV and HIV.
    Gut. 2016;65:718-20.
    PubMed     Text format    


    March 2016
  26. SAYED IM, Verhoye L, Cocquerel L, Abravanel F, et al
    Study of hepatitis E virus infection of genotype 1 and 3 in mice with humanised liver.
    Gut. 2016 Mar 22. pii: gutjnl-2015-311109. doi: 10.1136/gutjnl-2015-311109.
    PubMed     Text format     Abstract available


  27. ZHAO XL, Yang JR, Lin SZ, Ma H, et al
    Serum viral duplex-linear DNA proportion increases with the progression of liver disease in patients infected with HBV.
    Gut. 2016;65:502-11.
    PubMed     Text format     Abstract available


    February 2016
  28. RAJORIYA N, Feld JJ
    One small SNP for receptor virus entry, one giant leap for hepatitis B?
    Gut. 2016 Feb 18. pii: gutjnl-2015-311029. doi: 10.1136/gutjnl-2015-311029.
    PubMed     Text format    


  29. VERGIS N, Khamri W, Beale K, Sadiq F, et al
    Defective monocyte oxidative burst predicts infection in alcoholic hepatitis and is associated with reduced expression of NADPH oxidase.
    Gut. 2016 Feb 9. pii: gutjnl-2015-310378. doi: 10.1136/gutjnl-2015-310378.
    PubMed     Text format     Abstract available


  30. VISVANATHAN K, Dusheiko G, Giles M, Wong ML, et al
    Managing HBV in pregnancy. Prevention, prophylaxis, treatment and follow-up: position paper produced by Australian, UK and New Zealand key opinion leaders.
    Gut. 2016;65:340-50.
    PubMed     Text format     Abstract available


  31. XIN J, Ding W, Hao S, Chen X, et al
    Serum macrophage inflammatory protein 3alpha levels predict the severity of HBV-related acute-on-chronic liver failure.
    Gut. 2016;65:355-7.
    PubMed     Text format    


    January 2016
  32. POH Z, Shen L, Yang HI, Seto WK, et al
    Real-world risk score for hepatocellular carcinoma (RWS-HCC): a clinically practical risk predictor for HCC in chronic hepatitis B.
    Gut. 2016 Jan 19. pii: gutjnl-2015-310818. doi: 10.1136/gutjnl-2015-310818.
    PubMed     Text format    


  33. SERTI E, Park H, Keane M, O'Keefe AC, et al
    Rapid decrease in hepatitis C viremia by direct acting antivirals improves the natural killer cell response to IFNalpha.
    Gut. 2016 Jan 4. pii: gutjnl-2015-310033. doi: 10.1136/gutjnl-2015-310033.
    PubMed     Text format     Abstract available


  34. STOCKDALE AJ, Phillips RO, Geretti AM
    The gamma-glutamyl transpeptidase to platelet ratio (GPR) shows poor correlation with transient elastography measurements of liver fibrosis in HIV-positive patients with chronic hepatitis B in West Africa. Response to: 'The gamma-glutamyl transpeptida
    Gut. 2016 Jan 4. pii: gutjnl-2015-311133. doi: 10.1136/gutjnl-2015-311133.
    PubMed     Text format    


    December 2015
  35. VARCHETTA S, Mele D, Lombardi A, Oliviero B, et al
    Lack of Siglec-7 expression identifies a dysfunctional natural killer cell subset associated with liver inflammation and fibrosis in chronic HCV infection.
    Gut. 2015 Dec 16. pii: gutjnl-2015-310327. doi: 10.1136/gutjnl-2015-310327.
    PubMed     Text format     Abstract available


  36. HU HH, Liu J, Lin YL, Luo WS, et al
    The rs2296651 (S267F) variant on NTCP (SLC10A1) is inversely associated with chronic hepatitis B and progression to cirrhosis and hepatocellular carcinoma in patients with chronic hepatitis B.
    Gut. 2015 Dec 7. pii: gutjnl-2015-310686. doi: 10.1136/gutjnl-2015-310686.
    PubMed     Text format     Abstract available


    November 2015
  37. SUREAU C
    A unique monoclonal antibody for therapeutic use against chronic hepatitis B: not all antibodies are created equal.
    Gut. 2015 Nov 26. pii: gutjnl-2015-310978. doi: 10.1136/gutjnl-2015-310978.
    PubMed     Text format    


  38. PRENTOE J, Verhoye L, Velazquez Moctezuma R, Buysschaert C, et al
    HVR1-mediated antibody evasion of highly infectious in vivo adapted HCV in humanised mice.
    Gut. 2015 Nov 20. pii: gutjnl-2015-310300. doi: 10.1136/gutjnl-2015-310300.
    PubMed     Text format     Abstract available


  39. ZOULIM F, Liang TJ, Gerbes AL, Aghemo A, et al
    Hepatitis C virus treatment in the real world: optimising treatment and access to therapies.
    Gut. 2015;64:1824-33.
    PubMed     Text format     Abstract available


    September 2015
  40. ZHANG TY, Yuan Q, Zhao JH, Zhang YL, et al
    Prolonged suppression of HBV in mice by a novel antibody that targets a unique epitope on hepatitis B surface antigen.
    Gut. 2015 Sep 30. pii: gutjnl-2014-308964. doi: 10.1136/gutjnl-2014-308964.
    PubMed     Text format     Abstract available


    August 2015
  41. VERCAUTEREN K, Brown RJ, Mesalam AA, Doerrbecker J, et al
    Targeting a host-cell entry factor barricades antiviral-resistant HCV variants from on-therapy breakthrough in human-liver mice.
    Gut. 2015 Aug 25. pii: gutjnl-2014-309045. doi: 10.1136/gutjnl-2014-309045.
    PubMed     Text format     Abstract available


  42. STOHR S, Costa R, Sandmann L, Westhaus S, et al
    Host cell mTORC1 is required for HCV RNA replication.
    Gut. 2015 Aug 14. pii: gutjnl-2014-308971. doi: 10.1136/gutjnl-2014-308971.
    PubMed     Text format     Abstract available


  43. ZEISEL MB, Lucifora J, Mason WS, Sureau C, et al
    Towards an HBV cure: state-of-the-art and unresolved questions--report of the ANRS workshop on HBV cure.
    Gut. 2015;64:1314-26.
    PubMed     Text format     Abstract available


  44. DEUFFIC-BURBAN S, Yazdanpanah Y
    Fair prices for new direct-acting antiviral agents (DAAs) to make treatment for all affordable.
    Gut. 2015;64:1190-1.
    PubMed     Text format    


    July 2015
  45. KENG CT, Sze CW, Zheng D, Zheng Z, et al
    Characterisation of liver pathogenesis, human immune responses and drug testing in a humanised mouse model of HCV infection.
    Gut. 2015 Jul 6. pii: gutjnl-2014-307856. doi: 10.1136/gutjnl-2014-307856.
    PubMed     Text format     Abstract available


    June 2015
  46. MAJOR ME
    Hepatitis C: new clues to better vaccines?
    Gut. 2015 Jun 19. pii: gutjnl-2015-309829. doi: 10.1136/gutjnl-2015-309829.
    PubMed     Text format    


  47. VON DELFT A, Humphreys IS, Brown A, Pfafferott K, et al
    The broad assessment of HCV genotypes 1 and 3 antigenic targets reveals limited cross-reactivity with implications for vaccine design.
    Gut. 2015 Jun 19. pii: gutjnl-2014-308724. doi: 10.1136/gutjnl-2014-308724.
    PubMed     Text format     Abstract available


  48. TESTONI B, Durantel D, Lebosse F, Fresquet J, et al
    Ribavirin restores IFNalpha responsiveness in HCV-infected livers by epigenetic remodelling at interferon stimulated genes.
    Gut. 2015 Jun 16. pii: gutjnl-2014-309011. doi: 10.1136/gutjnl-2014-309011.
    PubMed     Text format     Abstract available


  49. NASSAL M
    HBV cccDNA: viral persistence reservoir and key obstacle for a cure of chronic hepatitis B.
    Gut. 2015 Jun 5. pii: gutjnl-2015-309809. doi: 10.1136/gutjnl-2015-309809.
    PubMed     Text format     Abstract available


  50. ZHANG DY, Goossens N, Guo J, Tsai MC, et al
    A hepatic stellate cell gene expression signature associated with outcomes in hepatitis C cirrhosis and hepatocellular carcinoma after curative resection.
    Gut. 2015 Jun 4. pii: gutjnl-2015-309655. doi: 10.1136/gutjnl-2015-309655.
    PubMed     Text format     Abstract available


  51. ANHE FF, Roy D, Pilon G, Dudonne S, et al
    A polyphenol-rich cranberry extract protects from diet-induced obesity, insulin resistance and intestinal inflammation in association with increased Akkermansia spp. population in the gut microbiota of mice.
    Gut. 2015;64:872-83.
    PubMed     Text format     Abstract available


    October 2014
  52. CAO Q, Imbeaud S, Datta S, Zucman-Rossi J, et al
    Authors' response: virus-host interactions in HBV-related hepatocellular carcinoma: more to be revealed?
    Gut. 2014 Oct 20. pii: gutjnl-2014-308482. doi: 10.1136/gutjnl-2014-308482.
    PubMed     Text format    


    September 2014
  53. CAO W, Peppelenbosch MP, Pan Q
    Virus-host interactions in HBV-related hepatocellular carcinoma: more to be revealed?
    Gut. 2014 Sep 8. pii: gutjnl-2014-308283. doi: 10.1136/gutjnl-2014-308283.
    PubMed     Text format    


    July 2014
  54. ARNDT S, Wacker E, Dorn C, Koch A, et al
    Enhanced expression of BMP6 inhibits hepatic fibrosis in non-alcoholic fatty liver disease.
    Gut. 2014 Jul 10. pii: gutjnl-2014-306968. doi: 10.1136/gutjnl-2014-306968.
    PubMed     Text format     Abstract available


    June 2014
  55. AMADDEO G, Cao Q, Ladeiro Y, Imbeaud S, et al
    Integration of tumour and viral genomic characterisations in HBV-related hepatocellular carcinomas.
    Gut. 2014 Jun 9. pii: gutjnl-2013-306228. doi: 10.1136/gutjnl-2013-306228.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Hepatitis is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: